27 Feb, 2025

Sorriso Pharmaceuticals Presents Positive SOR102 Phase 1b Ulcerative Colitis Data at ECCO Conference

27 Feb, 2025

Startup working on oral antibodies shares early ulcerative colitis data

19 Dec, 2024

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

19 Dec, 2024

Exclusive: Can oral antibodies work? A small startup thinks it has an answer

3 Sep, 2024

Sorriso Pharmaceuticals Completes Enrollment in Phase 1b Clinical Trial of Patients with Ulcerative Colitis

17 May, 2024

Sorriso Pharmaceuticals Announces First Patients Dosed in Phase 1b Clinical Trial for Patients with Ulcerative Colitis